{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:56:09Z","timestamp":1773370569031,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tata Memorial Hospital - TMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The therapeutic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in isolated cytology-positive (Cy\n                      <jats:sup>+<\/jats:sup>\n                      ) gastric cancer without peritoneal metastases (Peritoneal Cancer Index score 0) remains investigational. This study evaluated survival outcomes, prognostic factors, and exploratory HIPEC efficacy in Cy\n                      <jats:sup>+<\/jats:sup>\n                      patients treated with modern multimodal therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 558 patients with gastric adenocarcinoma who received neoadjuvant chemotherapy followed by radical gastrectomy (2017\u20132023). Propensity score matching (1:5) balanced 47 Cy\n                      <jats:sup>+<\/jats:sup>\n                      and 511 cytology-negative (Cy\n                      <jats:sup>\u2212<\/jats:sup>\n                      ) patients for pathologic stage, treatment response, and adjuvant completion. Inverse probability of treatment weighting validated matched results. Primary endpoints were overall survival (OS) and disease-free survival (DFS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cy\n                      <jats:sup>+<\/jats:sup>\n                      patients had inferior outcomes (median OS 24.7 vs. 57.2 months; hazard ratio [HR] 2.09;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001; DFS 14.7 vs. 41.4 months; HR 1.62;\n                      <jats:italic>p<\/jats:italic>\n                      =0.012), which persisted after matching and inverse probability of treatment weighting. Within the Cy\n                      <jats:sup>+<\/jats:sup>\n                      cohort, nodal metastasis was the strongest prognostic factor, tripling recurrence risk (DFS HR 3.06;\n                      <jats:italic>p<\/jats:italic>\n                      =0.018). Among 23 Cy\n                      <jats:sup>+<\/jats:sup>\n                      patients undergoing HIPEC, 2-year DFS was 41.4 versus 29.5% (\n                      <jats:italic>p<\/jats:italic>\n                      =0.398) and OS was 55.6 versus 42.4% (\n                      <jats:italic>p<\/jats:italic>\n                      =0.903) compared with non-HIPEC cases. HIPEC increased operative time and hospital stay but showed comparable morbidity and no 90-day mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cytology positivity independently predicted poor survival after curative gastrectomy, but nodal status was the dominant prognostic determinant. HIPEC was well tolerated but conferred no significant survival advantage, underscoring its investigational role pending prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18743-2","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:33:26Z","timestamp":1764095606000},"page":"2960-2971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of HIPEC in Isolated Cytology-Positive Gastric Cancer: Nodal Metastasis Dominates Prognosis, HIPEC Remains Unproven"],"prefix":"10.1245","volume":"33","author":[{"given":"Kunal","family":"Nandy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Parray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Dhaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Chopde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishnu","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat","family":"Bhargav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish S","family":"Bhandare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh V","family":"Shrikhande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram A","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"9","key":"18743_CR1","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3390\/cancers12092627","volume":"12","author":"S Rausei","year":"2020","unstructured":"Rausei S, Lianos GD. Treatment of gastric cancer. Cancers (Basel). 2020;12(9):2627.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"18743_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/IA9.0000000000000005","volume":"42","author":"GD Lianos","year":"2022","unstructured":"Lianos GD, Bali CD, Schizas D, Mitsis M, Galli F, Rausei S. Management of positive peritoneal cytology gastric cancer patients: current evidence. G Chir. 2022;42(3):e06.","journal-title":"G Chir."},{"issue":"1","key":"18743_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/cancers12010158","volume":"12","author":"S Ministrini","year":"2020","unstructured":"Ministrini S, Bencivenga M, Solaini L, Cipollari C, Sofia S, Marino E, et al. Stage IV gastric cancer: the surgical perspective of the Italian research group on gastric cancer. Cancers (Basel). 2020;12(1):158.","journal-title":"Cancers (Basel)."},{"issue":"32","key":"18743_CR4","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.12998\/wjcc.v9.i32.9711","volume":"9","author":"A Bausys","year":"2021","unstructured":"Bausys A, Gricius Z, Aniukstyte L, Luksta M, Bickaite K, Bausys R, et al. Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer. World J Clin Cases. 2021;9(32):9711\u201321.","journal-title":"World J Clin Cases."},{"key":"18743_CR5","first-page":"56526","volume":"131","author":"B Shi","year":"2018","unstructured":"Shi B, Lin H, Zhang M, Lu W, Qu Y, Zhang H. Gene regulation and targeted therapy in gastric cancer peritoneal metastasis: radiological findings from dual energy CT and PET\/CT. J Vis Exp. 2018;131:56526.","journal-title":"J Vis Exp."},{"issue":"24","key":"18743_CR6","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.3390\/cancers15245794","volume":"15","author":"A Bausys","year":"2023","unstructured":"Bausys A, \u00dcmarik T, Dobrzhanskyi O, Luksta M, et al. Neoadjuvant chemotherapy followed by gastrectomy for cytology-positive gastric cancer without any other non-curative factors in a western setting: an International Eastern European cohort study. Cancers (Basel). 2023;15(24):5794.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"18743_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/jso.25729","volume":"120","author":"CJ Allen","year":"2019","unstructured":"Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, et al. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019;120(8):1350\u20137.","journal-title":"J Surg Oncol."},{"issue":"10","key":"18743_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol."},{"issue":"1","key":"18743_CR9","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1038\/s41598-021-86352-6","volume":"11","author":"J Desiderio","year":"2021","unstructured":"Desiderio J, Sagnotta A, Terrenato I, Annibale B, Trastulli S, Tozzi F, et al. Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. Sci Rep. 2021;11(1):7150.","journal-title":"Sci Rep."},{"issue":"2","key":"18743_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21(2):315\u201323.","journal-title":"Gastric Cancer."},{"key":"18743_CR11","doi-asserted-by":"crossref","unstructured":"Japanese gastric cancer association 2023 Japanese gastric cancer treatment guidelines 2021 gastric Cancer. 2023 26 (1) 1\u201325","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"10","key":"18743_CR12","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1245\/s10434-024-15842-4","volume":"31","author":"S Batra","year":"2024","unstructured":"Batra S, Bhandare MS, Chaudhari V, Esha P, Nikhil M, Ostwal V, et al. Resected gastric adenocarcinomas at a single institution: outcomes and trends over 17 years. Ann Surg Oncol. 2024;31(10):7142\u201356.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"18743_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4103\/ijc.IJC_665_17","volume":"54","author":"MS Bhandare","year":"2017","unstructured":"Bhandare MS, Kumar N, Batra S, Chaudhari V, Shrikhande SV. Radical gastrectomy for gastric cancer at Tata memorial hospital. Indian J Cancer. 2017;54(4):605\u20138.","journal-title":"Indian J Cancer."},{"issue":"6","key":"18743_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.21037\/cco-23-90","volume":"12","author":"C Chen","year":"2023","unstructured":"Chen C, Justo M, Gangi A. Hyperthermic intraperitoneal chemotherapy for gastric cancer: a narrative review. Chin Clin Oncol. 2023;12(6):68.","journal-title":"Chin Clin Oncol."},{"issue":"9","key":"18743_CR15","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"18743_CR16","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","volume":"26","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Rihuete Caro C, P\u00e9rez-Viejo E, Serrano \u00c1, Gutierrez Calvo A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26(8):2615\u201321.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"18743_CR17","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","volume":"44","author":"CR Caro","year":"2018","unstructured":"Caro CR, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano A, P\u00e9rez-Viejo E. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805\u201310.","journal-title":"Eur J Surg Oncol."},{"key":"18743_CR18","doi-asserted-by":"crossref","unstructured":"World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects JAMA. 2013 310 (20) 2191\u201394","DOI":"10.1001\/jama.2013.281053"},{"key":"18743_CR19","doi-asserted-by":"crossref","unstructured":"Dindo D. The Clavien-Dindo classification of surgical complications. In: Treatment of postoperative complications after digestive surgery. 2014. p. 13\u20137.","DOI":"10.1007\/978-1-4471-4354-3_3"},{"issue":"3","key":"18743_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","volume":"15","author":"Y Kodera","year":"2012","unstructured":"Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335\u20137.","journal-title":"Gastric Cancer."},{"issue":"3","key":"18743_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bjs.7812","volume":"99","author":"SD Lee","year":"2012","unstructured":"Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012;99(3):397\u2013403.","journal-title":"Br J Surg."},{"issue":"2","key":"18743_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329\u201338.","journal-title":"Gastric Cancer."},{"issue":"1","key":"18743_CR23","doi-asserted-by":"publisher","first-page":"9549","DOI":"10.1038\/s41598-020-66637-y","volume":"10","author":"HJ Shim","year":"2020","unstructured":"Shim HJ, Kim HJ, Lee SH, Bae WK, Hwang EC, Cho SH, et al. Observational study of peritoneal washing cytology-positive gastric cancer without gross peritoneal metastasis in patients who underwent radical D2 gastrectomy. Sci Rep. 2020;10(1):9549.","journal-title":"Sci Rep."},{"issue":"3","key":"18743_CR24","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","volume":"30","author":"BL Green","year":"2023","unstructured":"Green BL, Blumenthaler AN, Gamble LA, McDonald JD, Robinson K, Connolly M, Epstein M, Hernandez JM, Blakely AM, Badgwell BD, Davis JL. Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Annals of surgical oncology. 2023;30(3):1852\u201360.","journal-title":"Annals of surgical oncology."},{"issue":"1","key":"18743_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","volume":"27","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Ann Surg Oncol. 2020;27(1):284\u201392.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"18743_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12957-023-03085-8","volume":"21","author":"B Li","year":"2023","unstructured":"Li B, Miao R, Shan F, Li S, Jia Y, Xue K, et al. Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology. World J Surg Oncol. 2023;21(1):204.","journal-title":"World J Surg Oncol."},{"key":"18743_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1\u20134.","journal-title":"Eur J Cancer."},{"issue":"1","key":"18743_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20(1):128\u201334.","journal-title":"Gastric Cancer."},{"key":"18743_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02351-x","volume":"19","author":"M Valletti","year":"2021","unstructured":"Valletti M, Eshmuminov D, Gnecco N, Gutschow CA, Schneider PM, Lehmann K. Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World Journal of Surgical Oncology. 2021;19:1\u20138.","journal-title":"World Journal of Surgical Oncology."},{"key":"18743_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-183","volume":"14","author":"O Glehen","year":"2014","unstructured":"Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC cancer. 2014;14:1.","journal-title":"BMC cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18743-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:42Z","timestamp":1773330462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18743"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18743-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}